One of the most popular ways to lose weight today is ozempic and its analogues, but these are not the most effective drugs in the fight against excess weight, says Marina Berkovskaya, Associate Professor of the Department of Endocrinology at Sechenov University of the Ministry. Health of Russia told socialbites.ca.
One of such drugs is Munjaro (tirzepatide), the effect of which is comparable to bariatric surgery (surgical treatment of obesity).
“This is a dual agonist of gastrointestinal hormones involved in the regulation of human eating behavior. It has proven to be more effective in the treatment of diabetes and obesity. New molecules are also being studied today. For example, retatrutide is already a triple agonist drug, but it is only in the third phase of research. So far data show that the effect of weight loss is comparable to bariatric surgery,” Berkovskaya noted.
Ozempic, known in Russia, was developed in Denmark, and its Russian analogues are based on the same active ingredient, semaglutide. This substance mimics the action of a hormone produced by the body when eating that helps the pancreas produce insulin when glucose levels are high. This keeps you feeling full for longer.
In addition, the drug affects the nutritional center in the hypothalamus, leading to a serious decrease in appetite and, as a result, rapid weight loss.
“This group of drugs is not new; the first glucagon-like peptide type 1 receptor agonists came to market around 2007. These drugs are glucose-lowering drugs and are used to treat type 2 diabetes, but as new data emerged it became clear that they had another additional effect: weight loss.” loss. Since most patients with type 2 diabetes are truly obese, doctors really appreciated this additional effect,” Berkovskaya told socialbites.ca.
Learn more about what new methods exist to combat obesity and what the dangers of long-term use of ozepic analogues are. material “socialbites.ca”.
Previously recognizedThe dangers of obesity in late pregnancy.